Skip to content
Medical Health Aged Care, Research Development

New analysis uncovers reality about Government public health and prevention research funding

Public Health Association of Australia / Australian and New Zealand Journal of Public Health 3 mins read

As Australia’s health system struggles with the growing burden of preventable disease, new analysis published today provides important insights into Government research funding that is designed to help keep Australians healthy and out of hospitals. 

The new examination of projects and grants issued through the Australian Government’s Medical Research Future Fund (MRFF) is the first of its kind and has been published today in the Australian and New Zealand Journal of Public Health.

Researchers found that despite public health being a clear priority for the MRFF, many research projects classified as being about ‘public health’ or ‘prevention’ were more focussed on clinical aspects, such as treatment and cure.

Paper co-author Hon. Associate Professor Leanne Coombe, from The University of Queensland, is also Manager of Policy and Advocacy at the Public Health Association of Australia. She says the findings demonstrate there is confusion around the definition of public health, and inadequate transparency when it comes to public health research funding in Australia.

“We have all heard the old adage that ‘prevention’ is better than ‘cure' – and in public health research we are looking for ways to keep people healthy and stop people getting sick. 

“We are also looking at what can be done to improve health at a population, rather than individual, level and to address the causes of health inequities between sub-groups within the population.

“So we examined research projects funded through key MRFF Initiatives related to public health, to uncover what type of research was being conducted and how much funding they were receiving.

“One of the most ironic and concerning findings related to project funding granted through the MRFF’s specific 'Preventive and Public Health Research' Initiative. This Initiative is meant to focus on public health and over $238.8m in funding has been distributed under this banner since 2018.

“Counterintuitively, less than half of the research projects funded under this Initiative were actually public health-focused. This translates to less than 40c in every $1 spent in this Initiative truly going to public health and prevention.  

“Even within those projects that were ‘prevention’ focused, there was little focus on primary prevention research – initiatives that stop Australians from getting sick in the first place, rather than early detection, treatment or slowing disease progression.

“To take the burden off the health system, we need to invest in genuine public health and prevention research,” Associate Professor Coombe says.

Dr Saman Khalatbari-Soltani from the University of Sydney School of Public Health says that a lack of public health and prevention focused research was also found in other MRFF Initiatives. 

“The MRFF has 22 funded Initiatives. Overall, we found that only 57 percent of the 249 projects and around half of the funding granted through the six public health-related Initiatives included in the study was for genuine public health research. 

“While the projects funded may still be very worthy and while there may be other public health projects funded through other Initiatives not analysed in this study, it appears that prevention is taking a backseat to clinical research.

“In Australia today there are unfair and avoidable differences in health between different population groups, and this is one of our biggest public health challenges. To address this, funding needs to prioritise public health projects that target the root causes behind these inequities, such as our living conditions, our work, our social supports and so on.”

Adjunct Professor Terry Slevin, CEO, Public Health Association of Australia, says a lack of genuine transparency around public health research in Australia is just part of the problem. 

“Across the board health prevention initiatives are grossly and outrageously underfunded, while treatment and clinical initiatives attract billions of dollars. For example, Australia has an 85-page National Health Prevention Strategy with virtually no funding attached to it.   

“Everyone wants effective accessible treatment for existing disease. But the cost of treating them, particularly chronic diseases, is skyrocketing. If we do not boost investment in prevention, we will continue to suffer from, treat and pay for preventable chronic diseases for generations to come.  Proper commitment to prevention research is a step in that direction. 

“Australia has a Pharmaceutical Benefits Scheme and Advisory Committee that determines which proven medical treatments are funded by government to make sure Australians can benefit from them. It’s time Australia revisited how we fund public health research and programs, and created a similar model to ensure that proven, effective public health initiatives get the funds they need.” 

ENDS

For media enquiries, please contact:

Hollie Harwood, Strategic Communications Advisor, Public Health Association of Australia / Australian and New Zealand Journal of Public Health: hharwood@phaa.net.au, 0400 762 010

Note to editors:

“Public health and prevention research within the Medical Research Future Fund” by Benedicta Natalia Latif, Leanne Coombe, Tim Driscoll, Anita van Zwieten, Catherine Sherrington & Saman Khalatbari-Soltani has been published online here

Please credit the Australian and New Zealand Journal of Public Health. The Journal is the official publication of the Public Health Association of Australia.

All articles are open access and can be found here: https://www.journals.elsevier.com/australian-and-new-zealand-journal-of-public-health

 

More from this category

  • Medical Health Aged Care
  • 27/12/2024
  • 17:11
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia…

  • Contains:
  • Medical Health Aged Care
  • 23/12/2024
  • 22:11
BeiGene, Ltd.

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN MATEO, Calif.–BUSINESS WIRE– BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne…

  • Contains:
  • Medical Health Aged Care
  • 23/12/2024
  • 12:57
Royal Australian College of GPs

RACGP: Look after your mental health this holiday season

The Royal Australian College of GPs (RACGP) has urged Australians to look after themselves and their loved ones this holiday season. College President, Dr Michael Wright, said that reaching out and helping others can make all the difference. “The holiday season can be a challenging time for many Australians,” he said. “Many of us can have family and relationship pressures, financial pressures may become more obvious, and isolation and loneliness can be at their worst this time of year too. So, during this festive season please try to look after yourself and the people in your life. It can be…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.